Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9H4B0
UPID:
OSGL1_HUMAN
Alternative names:
N6-L-threonylcarbamoyladenine synthase; O-sialoglycoprotein endopeptidase-like protein 1; t(6)A37 threonylcarbamoyladenosine biosynthesis protein OSGEPL1; tRNA threonylcarbamoyladenosine biosynthesis protein OSGEPL1
Alternative UPACC:
Q9H4B0; Q96EV9; Q96NH5
Background:
The tRNA N6-adenosine threonylcarbamoyltransferase, mitochondrial, known by alternative names such as N6-L-threonylcarbamoyladenine synthase and OSGEPL1, plays a crucial role in mitochondrial tRNA modification. It is essential for the formation of a threonylcarbamoyl group on adenosine at position 37 in mitochondrial tRNAs that read codons beginning with adenine, facilitating mitochondrial genome maintenance.
Therapeutic significance:
Understanding the role of tRNA N6-adenosine threonylcarbamoyltransferase could open doors to potential therapeutic strategies.